Mast cells and mastocytosis

Blood

Volumn 112, Issue 4, 2008, Pages 946-956

  Metcalfe, Dean D ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALPHA INTERFERON; ANTIHISTAMINIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CHYMASE; CLADRIBINE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; GLUCOCORTICOID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTAMINE; IMATINIB; IMMUNOGLOBULIN E; IMMUNOGLOBULIN RECEPTOR; INTERLEUKIN 13; INTERLEUKIN 16; INTERLEUKIN 3; INTERLEUKIN 5; INTERLEUKIN 6; LEUKOTRIENE DERIVATIVE; PEPTIDASE; PROTEIN KIT; PROTON PUMP INHIBITOR; STEM CELL FACTOR; TRYPTASE; UNCLASSIFIED DRUG; VASCULOTROPIN; VINCRISTINE; VITAMIN D;

ANAPHYLAXIS; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; BONE PAIN; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL IMMUNOLOGY; COLLAPSE; DEPRESSION; DRUG INHIBITION; FATIGUE; FEVER; GENE MUTATION; HUMAN; INFLAMMATION; INNATE IMMUNITY; MAST CELL; MASTOCYTOSIS; MYALGIA; NONHUMAN; OSTEOPOROSIS; PANCYTOPENIA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; ANIMAL; CHEMISTRY; CYTOLOGY; IMMUNOLOGY; PATHOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; INFLAMMATION; MAST CELLS; MASTOCYTOSIS; SIGNAL TRANSDUCTION;

EID: 51649115383     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-11-078097     Document Type: Article

References (110)

1. Cavalcante M, Allodi S, Valente A, et al. Occurrence of heparin in the invertebrate styela plicata (tunicata) is restricted to cell layers facing the outside environment. J Biol Chem. 2000;275:36189- 36196.
2. Malone DG, Metcalfe DD. Demonstration and characterization of a transient arthritis in rats following sensitization of synovial mast cells with antigen-specific IgE and parenteral challenge with specific antigen. Arthritis Rheum. 1998;31:1063-1067.
3. Nigrovic PA, Binstadt BA, Monach PA, et al. Mast cells contribute to initiation of autoantibody-mediated arthritis via lL-1. Proc Natl Acad Sci USA. 2007;104:2325-30.
4. Brown JM, Swindle EJ, Kushnir-Sukhov NM, Holian A, Metcalfe DD. Silica directed mast cell activation is enhanced by scavenger receptors. Am J Respir Cell Mol Biol. 2007;36:43-52.
5. Ehrlich P. Beitrage zur theorie und praxis der histologischen färbung [thesis]. Leipzig, Germany: University of Leipzig; 1878.
6. Unna PG. Die spezifische färbung der mastzellenkörnung. Monatsh Prakt Dermatol. 1894;19:367-368.
7. Webb RL. Peritoneal reactions in the white rat, with especial reference to the mast cells. Am J Anat. 1931;49:283-334.
8. Jorpes JE. The site of formation of heparin. In: Jorpes, JE. Heparin: Its Chemistry, Physiology, and Application in Medicine. London, United Kingdom: Humphrey Milford (Oxford Univ Press);1939:30-39.
9. Riley JF. Histamine in tissue mast cells. Science. 1953;118:332-333.
10. Diamant B, Högberg B, Thon IL. Isolation of biologically intact mast cells. Exp Cell Res. 1959;18:512-520.
11. Austin KF, Brocklehurst WE. Anaphylaxis in chopped guinea pig lung. II. Enhancement of the anaphylactic release of histamine and slow reacting substance by certain dibasic aliphatic acids and inhibition by monobasic fatty acids. J Exp Med. 1961;113:541-557.
12. Baker AR, Bloch KJ, Austen KF. In vitro passive sensitization of chopped guinea pig lung by guinea pig 7s antibodies. J Immunol. 1964;93:525-31.
13. Orange RP, Valentine MD, Austen KF. Antigen- induced release of slow reacting substance of anaphylaxis (SRS-Arat) in rats prepared with homologous antibody. J Exp Med. 1968;127:767-782.
14. Nettleship E, Tay W. Rare forms of urticaria. Br Med J. 1869;2:323-330.
15. Sangster A. An anomalous mottled rash, accompanied by pruritus, factitious urticaria and pigmentation, "urticaria pigmentosa?" Trans Clin Soc London. 1878;11:161-163.
16. Ellis JM. Urticaria pigmentosa: a report of a case with autopsy. AMA Arch Pathol. 1949;48:426-435.
17. Degos R. Les mastocytoses. Bull Soc Med Hôp (Paris). 1956;72:111-121.
18. Valent P, Horny H-P, Li C, et al. Mastocytosis. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours: Pathology and Genetics in Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:291-302.
19. Valent P, Akin C, Escribano L. Standards and standardization in mastocytosis: consensus statement on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37:435-453.
20. Brown JM, Wilson TM, Metcalfe DD. The mast cell and allergic diseases: role in pathogenesis and implications for therapy. Clin Exp Allergy. In press.
21. Saavedra-Delgado AMP, Turpin S, Metcalfe DD. Typical and atypical mast cells of the rat gastrointestinal system: distribution and correlation with tissue histamine. Agents Action. 1984;14:1-7.
22. Kushnir-Sukhov NM, Brown JM, Wu Y, Kirshenbaum A, Metcalfe DD. Human mast cells are capable of serotonin synthesis and release. J Allergy Clin Immunol. 2007;11:498-499.
23. Metcalfe DD, Lewis RA, Silbert JE, Rosenberg RD, Wasserman SI, Austen KF. Isolation and characterization of heparin from human lung. J Clin Invest. 1979;64:1537-1543.
24. Gilead L, et al. Human gastric mucosal mast cells are chondroitin sulphate E-containing mast cell. Immunology. 1987;62:23-28.
25. Metcalfe DD, Smith JA, Austen KF, Silbert JE. Polydispersity of rat mast cell heparin: implications for proteoglycan assembly. J Biol Chem. 1980;255:11753-11758.
26. Bourdon MA, Oldberg A, Pierschbacher M, Rusolahti E. Molecular cloning and sequence analysis of a chondroitin sulfate proteoglycan cDNA. Proc Natl Acad Sci U SA. 1985;82:1321-1325.
27. Avraham S, Stevens RL, Nicodemus CF, Gartner MC, Austen KF, Weis JH. Molecular cloning of a cDNA that encodes the peptide core of a mouse mast cell secretory granule proteogylcan and comparison with the analogous rat and human cDNA. Proc Natl Acad Sci USA. 1989;86:3763-3767.
28. Metcalfe DD, Thompson HL, Klebanoff SJ, Henderson WR. Oxidative degradation of rat mast cell heparin proteogylcan. Biochem J. 1990;272:51-57.
29. Schwartz LB, Bradford TR. Regulation of tryptase from human lung mast cells by heparin: stabilization of the active tetramer. J Biol Chem. 1986;261:7372-7379.
30. Caughey GH. Mast cell tryptases and chymases inflammation and host defense. Immunol Rev. 2007;217:141-154.
31. Iran A-MA, Garriga MM, Metcalfe DD, Schwartz LB. Mast cells in cutaneous mastocystosis: accumulation of the MC TC type. Clin Exp Allergy. 1990;20:53-58.
32. IshizakaT, Ishizaka K, Orange RP, Austen KF. The capacity of human immunoglobulin E to mediate the release of histamine and slowreacting substance of anaphylaxis (SRS-A) from monkey lung. J Immunol. 1970;104:335-343.
33. Murphy RC, Hammarstrom S, Samuelsson B. Leukotriene C: a slow-reacting substance from murine mastocytoma cells. Proc Natl Acad Sci U S A. 1979;76:4275-4279.
34. Hsieh FH, Lam BK, Penrose JF, Austen KF, Boyce JA. T helper cell type 2 cytokines coordinately regulate immunoglobulin E-dependent cysteinyl leukotriene production by human cord blood-derived mast cells: profound induction of leukotriene C4 synthase expression by interleukin 4. J Exp Med. 2001;193:123-133.
35. Soter NA, Lewis RA, Corey EJ, Austen KF. Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4 and LTB4) in human skin. J Invest Derma- tol. 1983;80:115-119.
36. Weiss JW, Drazen JM, Coles N, et al. Broncho- constrictor effects of leukotriene C in humans. Science. 1982;216:196-198.
37. Plaut M, Pierce JH, Watson CJ, Hanley-Hyde J, Nordan RP, Paul WE. Mast cell lines produce lymphokines in response to cross-linkage of Fc epsilon RI or to calcium ionophores. Nature. 1989;339:64-67.
38. Gordon JR, Galli SJ. Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin. Nature. 1990;346:274-276.
39. Ehrenreich H, Burd PR, Rottem M, et al. Endothelins belong to the assortment of mast cell derived and mast cell associated cytokines. New Biologist. 1992;4:147-156.
40. Rumsaeng V, Cruikshank WW, Foster B, et al. Human mast cells produce the CD4+ T lymphocyte chemoattractant factor, IL-16. J Immunol. 1997;159:2904-2910.
41. Nilsson G, Forsberg-Nilsson K, Hallbook F, Nilsson K, Metcalfe DD. Human mast cells express functional TRKA and are a source of nerve growth factor. Eur J Immunol. 1997;27:2295- 2301.
42. Okayama Y, Hagaman DD, Metcalfe DD. A comparison of mediators released or generated by IFN-γ treated human mast cells following aggregation of FcγRI or FcγRI aggregation. J Immunol. 2001;166:4705-4712.
43. Hagaman DD, Okayama Y, Ambrosio CD, Gilfillan AM, Prussin C, Metcalfe DD. Secretion of interleukin-1 receptor antagonist from human mast cells following IgE mediated activation and following segmental antigen challenge. Am J Resp Cell Mol Biol. 2001;25:685-691.
44. Devouassoux G, Foster B, Scott LM, Metcalfe DD, Prussin C. Frequency and characterization of antigen-specific IL-4 and IL-13 producing basophils and T cells in peripheral blood of normals and asthmatics. J Allergy Clin Immunol. 1999; 104:811-819.
45. Kulka M, Alexopoulou L, Flavell RA, Metcalfe DD. Activation of mast cells bydouble-stranded RNA: evidence for activation through toll-like receptor-3 (TLR-3). J Allergy Clin Immunol. 2004;114:174-182.
46. Kitamura Y, Shumada M, Hatanaka K, Miyano Y. Development of mast cells from grafted bone marrow cells in irradiated mice. Nature. 1977;268:442-443.
47. Nabel G, Galli SJ, Dvorak AM, et al. Inducer T lymphocytes synthesize a factor that stimulates proliferation of cloned mast cells. Nature. 1981;291:332-334.
48. Ihle JN, Keller J, Oroszlan S, et al. Biologic properties of homogenous interleukin 3. J Immunol. 1983;131:282-287.
49. Kirshenbaum AS, Goff JP, Irani A-M, Schwartz LB, Metcalfe DD. Interleukin 3-dependent growth of basophil-like cells and mast-like cells from human bone marrow. J Immunol. 1989;83:595-601.
50. Valent P, Schmidt G, Besemer J, et al. Interleu- kin-3 is a differentiation factor for human basophils. Blood. 1989;73:1763-1769.
51. Kirshenbaum AS, Kessler SW, Goff JP, Metcalfe DD. Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. J Immunol. 1991;146:1410-1415.
52. Zsebo KM, Wypych McNiece IK, et al. Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver-conditioned medium. Cell. 1990;63:195-201.
53. Huang E, Nocka K, Beier DR, et al. The hemato- poietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell. 1990;63:225- 233.
54. Anderson DM, Lyman SD, Baird A, et al. Molecular cloning of mast cell growth factor: hematopoietin that is active in both membrane bound and soluble forms. Cell. 1990;63:235-243.
55. Kirshenbaum AS, Goff JP, Kessler SW, Mican JM, Zsebo KM, Metcalfe DD. The effect of IL-3 and stem cell factor on the appearance of mast cells and basophils from CD34+ pluripotent progenitor cells. J Immunol. 1992;148:772-777.
56. Valent P, Spanblochl E, Sperr WR, et al. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant stem cell factor/kit-ligand in longterm culture. Blood. 1992;80:2237-2245.
57. Kirshenbaum AS, Goff JP, Semere T, Scott LM, Metcalfe DD. Demonstration that human mast cells arise from a bipotential progenitor cell population that is CD34 + c-kit+, and expresses aminopeptidase N (CD13). Blood. 1999;94:2333-2342.
58. Kirshenbaum AS, Worobec AS, Davis TA, Goff JP, SemereT, Metcalfe DD. Inhibition of human mast cell growth and differentiation by interferon gamma-1β. Exp Hematol. 1998;26:245-251.
59. Kulka M, Metcalfe DD. High resolution tracking of cell division demonstrates differential effects of TH-1 and TH-2 cytokines on SCF-dependent human mast cell production in vitro: correlation with apoptosis and Kit expression. Blood. 2005;105:592-599.
60. Bagga S, Price KS, Lin DA, Friend DS, Austen KF, Boyce JA. Lysophosphatidic acid accelerates the development of human mast cells. Blood. 2004;104:4080-4087.
61. Jiang Y, Kanaoka Y, Feng C, Nocha K, Rao S, Boyce JA. Cutting edge: interleukin 4-dependent mast cell proliferation requires autocrine/intracrine cysteinyl leukotriene-induced signaling. J Immunol. 2006;177:2755-2759.
62. Kirshenbaum AS, Akin C, Goof JP, Metcalfe DD. Thrombopoietin alone or in the presence of stem cell factor supports the growth of KIT (CD117)low/MPL (CD110)+ human mast cells from hematopoietic progenitor cells. Exp Hematol. 2005;33:413-421.
63. Besmer P, Murphy JE, George PC, et al. Anew acute transforming feline retrovirus and relationship of its oncogene v-kit with protein kinase gene family. Nature. 1986;320:415-421.
64. Akin C, Metcalfe DD. The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol. 2004;114:13-19.
65. Galli SJ, Tsai M, Wershil BK. The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others. Am J Pathol. 1993;965-974.
66. Prausnitz C, Kustner H. Studien üpber die VerberempFindlichkeit. Z Bakt. 1921;86:160-163.
67. Ishizaka K, Ishizaka T, Hornbrook MM. Physio-chemical properties of reagenic antibody: V correlation of reaginic activity with γε globulin antibody. J Immunol. 1966;97:840-853.
68. Johansson SG, Bennich H. Immunological studies of an atypical myeloma immunoglobulin. Immunology. 1967;13:381-394.
69. Malveaux FJ, Conroy MC, Adkinson NF Jr, Lichtenstein LM. IgE receptors on human basophils. Relationship to serum IgE concentration. J Clin Invest. 1978;62:176-181.
70. Blank U, Ra C, Miller L, White K, Metzger H, Kinet JP. Complete structure and expression in transfected cells of high affinity IgE receptor. Nature. 1989;337:187-189.
71. Miller L, Blank U, Metzger H, Kinet JP. Expression of high-affinity binding of human immunoglobulin E by transfected cells. Science. 1989;244:334-337.
72. Benhamou M, Gutkind JS, Robbins KC, Siraganian RP. Tyrosine phosphorylation coupled to IgE receptor-mediated signal transduction and histamine release. Proc Natl Acad Sci U S A. 1990;87:5327-5330.
73. Paolini R, Jouvin MH, Kinet JP. Phosphorylation and dephosphorylation of the high-affinity receptor for immunoglobulin E immediately after receptor engagement and disengagement. Nature. 1991;353:855-858.
74. Parravicin V, Gadina M, Kovarova M, et al. Fyn kinase initiates complementary signals required for IgE-dependent mast cell degranulation. Nat Immunol. 2002;3:741-748.
75. Tkaczyk C, Horejsi V, Iwaki S, et al. NTAL phosphorylation is a pivotal link between the signaling cascades leading to human mast cell degranulation following Kit activation and FcεR1 aggregation. Blood. 2004;104:207-214.
76. Kawakami T, Kitaura J. Mast cell survival and activation by IgE in the absence of antigen: a consideration of the biologic mechanisms and relevance. J Immunol. 2005;175:4167-4173.
77. Okayama Y, Kirshenbaum AS, Metcalfe DD. Expression of a functional high affinity IgG receptor (FcyRI) on human mast cells: up-regulation by IFN-γ. J Immunol. 2000;164:4332-4339.
78. Echtenacher B, Mannel DN, Hultner L. Critical protective role of mast cells in a model of acute septic peritonitis. Nature. 1996;381:75-77.
79. Maurer M, Echtenacher B, Hultner L, et. al. The c-kit ligand, stem cell factor, can enhance innate immunity through effects on mast cells. J Exp Med. 1998;188:2343-2348.
80. Metcalfe DD. Classification and diagnosis of mastocytosis: current status. J Invest Dermatol. 1991;96:2S-4S.
81. Longley BJ, Morganroth GS, Tyrrell L, et al. Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous mastocytosis. N Engl J Med. 1993;328:1302-1307.
82. Brockow K, Akin C, Huber M, Scott LM, Schwartz LB, Metcalfe DD. Levels of mast cell growth factors in plasma and in suction skin blister fluid in adults with mastocytosis: correlation with dermal mast cell numbers and mast cell tryptase. J Allergy Clin Immunol. 2002;109:82-88.
83. Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the proto-oncogene c-kit in the peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U SA. 1995;92:10560-10564.
84. Longley BJ, Tyrrell L, Lu SZ, et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet. 1996;12:312-314.
85. Furitsu T, TsujimuraT, TonoT, et al. Identification of mutations in the coding sequence of the protooncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest. 1993;92:1736-1744.
86. Valent P, Akin C, Sperr WR, et al. Mastocytosis: Pathology, genetics, and current opinions for therapy. Leuk Lymphoma. 2005;46:35-48.
87. Akin C, Metcalfe DD. The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol. 2004;114:13-19.
88. Daley T, Metcalfe DD, Akin C. Association of the Q576R polymorphism in the interleukin-4 receptor α chain with indolent mastocytosis limited to the skin. Blood. 2001;98:880-882.
89. Lahortiga I, Akin C, Cools J, et al. Activity of ima- tinib in systemic mastocytosis with chronic basophilic leukemia and PRKG2-PDGFRB fusion. Haematologica. 2008;93:49-56.
90. Maric I, Robyn J, Metcalfe DD, et al. KIT D816V- associated systemic mastocytosis with eosinophilia and FIP1L1/ PDGFRA-associated chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol. 2007;120:680-687.
91. Lawrence JB, Friedman BS, Travis WD, Chinchilli VM, Metcalfe DD, Gralnick R. Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. Am J Med. 1991;91:612-624.
92. Escribano L, Orfao A, Diaz-Agustin B, et al. Indolent system mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood. 1998;91:2731-2736.
93. Soltar K, Horney HP, Simonitsch I, et al. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic nastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol. 2004;28:1319-1325.
94. Travis WD, Li CY, Hoagland HC, et al. Mast cell leukemia: report of a case and review of the literature. Mayo Clin Proc. 1986;61:957-966.
95. Worobec AS, Akin C, Scott LM, Metcalfe DD. Cytogenetic abnormalities and their lack of relationship to the Asp816Val c-kit mutation in the patho-genesis of mastocytosis. J Allergy Clin Immunol. 1998;102:523-524.
96. Worobec AS. Treatment of systemic mast cell disorders. Hematol Oncol Clin North Am. 2000;14: 659-687.
97. Valent P, Gannadan M, Akin C, et al. On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts. Eur J Clin Invest. 2004;34(suppl 2):41-52.]
98. Kluin-Nelemans HC, Jansen JH, Breukelman H, et al. Response to interferon alfa 2b in a patient with systemic mastocytosis. N Engl J Med. 1992;326:619-623.
99. Valent P, Akin C, Sperr WR, et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res. 2003;27:635-641.
100. Tefferi A, Li CY, Butterfield JH, Hoagland HC. Treatment of systemic mast-cell disease with cladribine. N Engl J Med. 2001;344:307-309.
101. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood. 2003;102:4270-4276.
102. Akin C, Brockow K, D'Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol. 2003;31:686-692.
103. Ma Y, Zeng S, Metcalfe DD, et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood. 2002;99:1741-1744.
104. Pardanani A, Elliott M, Reeder T, et al. Imatinib for systemic mast-cell disease. Lancet. 2003;362:535-536.
105. Musto P, Falcone A, Sanpaolo G, Bodenizza C, Carella AM. Inefficacy of imatinib-mesylate in sporadic, aggressive systemic mastocytosis. Leuk Res. 2004;28:421-422.
106. Akin C, Fumo G, Yavuz AS, et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood. 2004;103:3222-3225.
107. Friedman B, Darling G, Norton J, Hamby L, Metcalfe D. Splenectomy in the management of systemic mast cell disease 205. Surgery. 1990;107:94-100.
108. Przepiorka D, Giralt S, Khouri I, Champlin R, Bueso-Ramos C. Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am J Hematol. 1998;57:24-28.
109. Nakamura R, Chakrabarti S, Akin C, et al. A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant. 2006;37:353-358.
110. Gotlib J, Berube C, Growney JD, et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood. 2005;106:2865-2870.